• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, April 5, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Immune study in chickens reveals key hurdle for Campylobacter vaccine effort

Bioengineer by Bioengineer
March 23, 2017
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

New University of Liverpool research reveals that the immune response of farmed chickens does not develop fast enough to fight off Campylobacter during their short lifespan. The findings have important implications in the challenge towards developing a poultry vaccine for the bug, which is the UK's leading cause of food poisoning.

As both a public health and animal welfare issue, finding a way to control Campylobacter infection is a priority for the poultry industry. There are currently no commercial vaccines and their development is hampered by poor understanding of the immunobiology of the infection.

In the first study of functional immunity to Campylobacter jejuni in the chicken, researchers have shown that antibody production plays a role, albeit limited, in the clearance of intestinal infection. However, it fails to clear the bacterium within the lifetime of a commercial broiler chicken, which is typically around six weeks of age.

Professor Paul Wigley, from the University's Institute of Infection and Global Health, said: "Our findings suggest that any Campylobacter vaccine relying solely on an antibody response is unlikely to be effective in broiler chickens."

Researchers carried out the study by chemically inhibiting the production of antibody-producing white blood cells (B lymphocytes) in broiler chicks, before introducing C.jejuni infection at the age of three weeks and then monitoring bacteria levels in the gut for the next nine weeks. They found that an antibody-associated drop in bacteria levels only became apparent after seven weeks and suggest that the adaptive immune response in the gut only begins to mature at six weeks of age.

Professor Wigley added: "It's likely to be very challenging to produce a protective immune response in broiler chickens before slaughter age, which is around six weeks of age."

"Vaccines that focus on a cell-mediated immune response, or alternatively some way of speeding up the production of antibodies in broiler chickens, may offer more promising routes to controlling Campylobacter, and ultimately reducing the amount of contaminated chicken in our supermarkets."

Approximately four in five cases of Campylobacter infection in the UK result from contaminated poultry – either through consumption of undercooked meat or through cross contamination in the kitchen. While good hygiene and thorough cooking can effectively prevent infection, there are still more than 280,000 cases in the UK and the cost to the economy is estimated at up to £900 million each year.

###

The work was funded by the Biotechnology and Biological Sciences Research Council (BBSRC) and the paper 'B lymphocytes play a limited role in clearance of Campylobacter jejuni from the chicken intestinal tract' is published in Scientific Reports.

Media Contact

Nicola Frost
[email protected]
@livuninews

http://www.liv.ac.uk

############

Story Source: Materials provided by Scienmag

Share12Tweet7Share2ShareShareShare1

Related Posts

Clinical Outcomes and Risks in Post-Ibrutinib Transplant

Clinical Outcomes and Risks in Post-Ibrutinib Transplant

April 5, 2026

Whole-Body MRI Predicts Ovarian Cancer Treatment Outcomes

April 5, 2026

Distributed Fusion Framework Predicts Breast Cancer Recurrence

April 5, 2026

Inside TCF3::HLF-Positive B-ALL: Clinical and Molecular Insights

April 5, 2026
Please login to join discussion

POPULAR NEWS

  • blank

    Revolutionary AI Model Enhances Precision in Detecting Food Contamination

    97 shares
    Share 39 Tweet 24
  • Promising Outcomes from First Clinical Trials of Gene Regulation in Epilepsy

    51 shares
    Share 20 Tweet 13
  • Imagine a Social Media Feed That Challenges Your Views Instead of Reinforcing Them

    1008 shares
    Share 398 Tweet 249
  • Popular Anti-Aging Compound Linked to Damage in Corpus Callosum, Study Finds

    44 shares
    Share 18 Tweet 11

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Clinical Outcomes and Risks in Post-Ibrutinib Transplant

Whole-Body MRI Predicts Ovarian Cancer Treatment Outcomes

Distributed Fusion Framework Predicts Breast Cancer Recurrence

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 78 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.